Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
CC transcript
SANTARUS INC (SNTS) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/02/2014 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "Third Amended and Restated Certificate of Incorporation of Santarus, Inc",
"Second Amended and Restated Bylaws of Santarus, Inc"
11/12/2013 8-K Quarterly results
11/07/2013 8-K Quarterly results
Docs: "Agreement and Plan of Merger, by and among Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Willow Acquisition Sub Corporation and Santarus, Inc",
"Tender and Support Agreement, by and among Salix Pharmaceuticals, Ltd., Willow Acquisition Sub Corporation and certain stockholders of Santarus, Inc",
"Amendment to Amended and Restated Bylaws of Santarus, Inc",
"SANTARUS REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Total revenues of $98.8 million grew 81% over prior year period Non-GAAP adjusted earnings of $35.6 million were up 189% over prior year period Santarus cancels conference call previously scheduled for 5:00 p.m. Eastern Time today",
"SALIX PHARMACEUTICALS TO ACQUIRE SANTARUS Solidifies Position as Largest U.S. Gastroenterology-Focused Specialty Pharmaceutical Company Provides Salix with an Experienced Specialty Sales Force to Significantly Expand Gastrointestinal Product Sales Increases Commercial Presence in Gastroenterology, Hepatology and Colorectal Surgery Estimated 2013 Pro Forma Total Product Revenue of $1.3 Billion Greatly Increases Scale and Revenue Diversification Expected to be Immediately and Significantly Accretive Expected to Generate Strong EBITDA and Cash from Operations Leading to Rapid Debt Repayment"
08/06/2013 8-K Quarterly results
Docs: "SANTARUS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Total revenues of $89.4 million grew 89% over prior year period Raises 2013 financial outlook to include total revenues of $355 million to $360 million, and non-GAAP adjusted earnings of $97 million to $101 million"
06/24/2013 8-K Other Events
06/18/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "SANTARUS AND PHARMING ANNOUNCE FDA ACCEPTANCE FOR REVIEW OF RUCONEST BIOLOGICS LICENSE APPLICATION"
05/10/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among Santarus, Inc., Cosmo Technologies Limited and Jefferies LLC",
"Opinion of Latham & Watkins LLP",
"SANTARUS ANNOUNCES LAUNCH OF A PROPOSED SECONDARY COMMON STOCK OFFERING BY A SELLING STOCKHOLDER",
"SANTARUS ANNOUNCES PRICING OF SECONDARY COMMON STOCK OFFERING BY A SELLING STOCKHOLDER"
05/06/2013 8-K Quarterly results
Docs: "SANTARUS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Total revenues increase 73% with significant increase in net income over prior year period Raises 2013 financial outlook to include total revenues of $330 million to $340 million, net income of $57 million to $64 million and non-GAAP adjusted earnings of $81 million to $91 million"
04/17/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "SANTARUS AND PHARMING ANNOUNCE SUBMISSION OF RUCONEST BIOLOGICS LICENSE APPLICATION TO FDA"
04/16/2013 8-K Other Events
03/04/2013 8-K Quarterly results
Docs: "SANTARUS REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS Company achieves record annual revenues of $218.0 million in 2012 2012 net income of $18.6 million and $0.27 diluted EPS more than triple prior year period"
02/22/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Santarus, Inc. 2013 Bonus Plan"
01/28/2013 8-K Other Events
01/23/2013 8-K Other Events
12/20/2012 8-K Other Events
12/19/2012 8-K Other Events
11/30/2012 8-K Entry into a Material Definitive Agreement
09/06/2012 8-K Form 8-K - Current report
08/15/2012 8-K Other Events
08/09/2012 8-K Other Events
08/07/2012 8-K Quarterly results
Docs: "SANTARUS REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Total revenues of $47.2 million grew 77% over prior year period Net income of $3.4 million increased 27% over 2011 second quarter Affirms 2012 financial outlook including revenues of at least $200 million"
08/06/2012 8-K Other Events
07/09/2012 8-K Form 8-K - Current report
06/15/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/15/2012 8-K Submission of Matters to a Vote of Security Holders
06/04/2012 8-K Resignation/termination of a director
05/22/2012 8-K Entry into a Material Definitive Agreement
05/08/2012 8-K Quarterly results
Docs: "SANTARUS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS Total revenues of $45.9 million more than double compared with the prior year period Affirms 2012 financial outlook"
04/18/2012 8-K Form 8-K - Current report
04/10/2012 8-K Regulation FD Disclosure
04/10/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/13/2012 8-K Regulation FD Disclosure
03/08/2012 8-K Other Events
03/05/2012 8-K Quarterly results
Docs: "SANTARUS REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS 2011 fourth quarter revenues of $42.6 million grew 65% over prior year period 2011 revenues totaled $118.8 million with net income of $4.7 million or $0.07 per diluted share"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy